Bioteknikbolaget Aptahem, som utvecklar läkemedelskandidaten Apta-1 mot sepsis, har tagit ett strate...
After announcing the proposed rights issue, we update our Base Case, including the number of shares.
Redeye provides an initial comment on Relais issuing cEUR50m in hybrid bonds to replace its recent b...
Atria announced today its TOGETHER 2030 strategy for 2025-30 with refined financial targets.
We initiate coverage of YIT with a REDUCE-rating and TP of EUR 3.
Första halvåret visade högre intäkter än föregående år, och tidiga beställningar inför tredje kvarta...
Nettoomsättningen steg 26 % till 18 mkr, drivet av egenutvecklade produkter (+44 % till 7,4 mkr) med...
Redeye comments on Verve's announced acquisition. The company is acquiring Acardo Group for EUR24.
Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an ...
Redeye is not surprised by the high subscription rate, considering the share has traded above the st...
Xplora is one of the leading players within smartwatches for kids and phones for seniors (65+), with...
Redeye is pleased with TO13’s preliminary subscription rate of 91%.
We have interviewed B Treasury Capital’s CEO, Christoffer De Geer.
Grangex nya DFS för Sydvaranger ökar visibiliteten och pekar på ytterligare värden.
Redeye returns with minor estimate changes following a mixed report from Binero that faced higher OP...
Redeye initiates coverage of Fractal Gaming Group, a Swedish premium gaming hardware brand best know...
Biovica continues to increase 12m rolling IVD test sales in Q1 of SEK 0.
Redeye briefly comments on Guard announcing that the data collection for the phase IIb study POINTER...
Redeye leaves its Base Case unchanged following limited estimate revisions.
Redeye comments on Acarix following recent news relating to the ownership structure, where, among ot...